Soligenix Announces Formation of Behçet’s Disease Medical Advisory Board
Phase 2a clinical study of SGX945 in Behçet’s Disease initiating in 2024
PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet’s Disease. The Company previously announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for dusquetide in the treatment of oral lesions of Behçet’s Disease.
Related news for (SNGX)
- Breaking News: MoBot’s Latest Update as of 09/23/25 07:00 AM
- Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
- 24/7 Market News Snapshot 23 September, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)
- 24/7 Market News Snapshot 04 September, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)
- Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses